CN113004241B - 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof - Google Patents

11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof Download PDF

Info

Publication number
CN113004241B
CN113004241B CN202110242717.7A CN202110242717A CN113004241B CN 113004241 B CN113004241 B CN 113004241B CN 202110242717 A CN202110242717 A CN 202110242717A CN 113004241 B CN113004241 B CN 113004241B
Authority
CN
China
Prior art keywords
benzoic acid
oridonin
dmso
nmr
dicarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202110242717.7A
Other languages
Chinese (zh)
Other versions
CN113004241A (en
Inventor
可钰
李富欣
王妮
贾小苹
赵梦圆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Henan Tobacco Company Jiyuan Co
Zhengzhou University
Original Assignee
Henan Tobacco Company Jiyuan Co
Zhengzhou University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Henan Tobacco Company Jiyuan Co, Zhengzhou University filed Critical Henan Tobacco Company Jiyuan Co
Priority to CN202110242717.7A priority Critical patent/CN113004241B/en
Publication of CN113004241A publication Critical patent/CN113004241A/en
Application granted granted Critical
Publication of CN113004241B publication Critical patent/CN113004241B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/96Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings spiro-condensed with carbocyclic rings or ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to natural productsAnd the field of medicinal chemistry, and discloses an 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative, a preparation method and application thereof. The preparation method comprises the following steps: the oridonin (JOA) is used as a starting material and is oxidized to obtain 11, 20-dicarbonyl oridonin, and then benzoic acid or substituted benzoic acid is subjected to esterification reaction with 14-OH of the oridonin to obtain a series of 11, 20-dicarbonyl oridonin 14-O-benzoic acid esterified derivatives on the premise of not damaging the active center alpha-methylene cyclopentanone. The compounds have good antitumor activity, and can be used for preparing anticancer drugs for treating esophageal cancer, gastric cancer, liver cancer, breast cancer, pancreatic cancer and other diseases. The general structural formula is as follows:

Description

11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof
Technical Field
The invention relates to the field of natural products and medicinal chemistry, in particular to an 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and a preparation method and application thereof.
Background
Rabdosia rubescens is plant of Rabdosia of Labiatae, and its application part is dried aerial part, and its effect is clearing heat and detoxicating, promoting blood circulation and relieving pain. A large number of researches show that the main anti-tumor active component in rabdosia rubescens is a diterpenoid compound, and the ent-kaurene diterpenoid is a natural compound with good anti-tumor effect, and documents report that the anti-tumor effect active center of the structure mainly depends on the molecular configuration and the cyclopentanone structure conjugated with exocyclic methylene, such as oridonin, rabdosia rubescens B, rabdosia leptandra and the like, and the anti-tumor effect active center of the structure has the anti-proliferation effect on various tumor cells in vitro, such as cancer cells of esophagus cancer, stomach cancer, breast cancer, cervical cancer, pancreatic cancer and the like.
The inventor separates the oridonin from the rabdosia rubescens ethanol extract by a series of methods in the earlier stage, and oxidizes the oridonin by using Jones reagent to obtain the required lead compound 11, 20-dicarbonyl oridonin. The in vitro antitumor activity shows that the compound has better antiproliferative effect on tumor cells and wider antitumor spectrum. Although most of the compounds have good anti-tumor effect, the defects of poor water solubility, poor stability, difficult oral absorption and the like generally exist, and the clinical application of the compounds is limited. The structural modification and reconstruction of the compounds are carried out to overcome the defects, and the problem of seeking a target compound with better pharmacy is the problem which needs to be solved urgently at present.
Disclosure of Invention
The invention aims to provide a series of Jiyuan oridonin derivatives, improve the anti-tumor effect, increase the bioavailability and increase the clinical application possibility of the Jiyuan oridonin.
The invention also aims to provide a preparation method and application thereof in preparing antitumor drugs.
In order to realize the purpose of the invention, hydroxyl at 11-position and 20-position of the oridonin from Jiyuan is oxidized into carbonyl, and then 14-OH of the oridonin is esterified with benzoic acid to obtain a series of derivatives, thus maintaining or enhancing the anti-tumor effect and simultaneously increasing the stability and bioavailability of the oridonin.
The structural general formula of the benzoic acid series derivative esterified by the 11, 20-dicarbonyl economic oridonin 14-OH is as follows:
Figure BDA0002962842810000021
wherein R is mono-substituted, di-substituted or polysubstituent on benzene ring, and R is selected from hydrogen; a methoxy group; a halogen; a nitro group; an amino group; a sulfonic acid group; a linear or branched alkyl group; straight chain alkyl substituted with halogen; a trifluoromethyl group.
R is preferably: hydrogen; c1-6 straight chain alkyl; c1-6 straight chain alkyl substituted with halogen; halogen; a nitro group; a methoxy group; a trifluoromethyl group.
R is preferably: hydrogen; a methoxy group; a methyl group; chlorine; bromine; fluorine; a trifluoromethyl group; iodine; a nitro group; a bromomethyl group.
The following groups after R substitution are more preferred:
Figure BDA0002962842810000022
the novel 11, 20-dicarbonyl economic oridonin 14-OH esterified benzoic acid series derivative is obtained by the following synthetic route:
Figure BDA0002962842810000023
1. dissolving separated and purified oridonin (JOA) in acetone, adding Jones reagent for reaction, adding isopropanol after the reaction is finished to quench the reaction, and purifying by column chromatography to obtain mother nucleus 11, 20-dicarbonyl oridonin.
2. Dissolving the obtained lead compound 11, 20-dicarbonyl economic oridonin in dichloromethane, adding corresponding benzoic acid, 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 4-Dimethylaminopyridine (DMAP) as catalysts under stirring to react, and purifying by column chromatography to obtain the target compound.
The invention has the advantages that: the invention selects oridonin (JOA) as a lead compound, obtains the required derivative through oxidation and esterification processes, has increased stability and better anti-tumor effect, can be used as a potential medicament for treating esophageal cancer, gastric cancer, liver cancer, breast cancer, pancreatic cancer and the like, and has important theoretical significance and practical application value for developing novel anti-tumor medicaments.
Detailed Description
The present invention is further illustrated by the following specific examples, but it should be noted that the scope of the present invention is not limited in any way by these examples.
Example 1:
Figure BDA0002962842810000031
weighing JOA 300mg, adding 11mL acetone to dissolve completely, adding 0.75mL Jones reagent (6mL acetone for dilution) under stirring condition for 20min, monitoring reaction by a dot plate, adding a certain amount of isopropanol to quench reaction, performing reduced pressure spin-drying after 20min, adding 30mL ethyl acetate to dilute the reaction system, washing the reaction system with saturated NaCl solution for three times, performing back extraction on the water phase with ethyl acetate once, drying the combined organic phase with anhydrous magnesium sulfate, concentrating, and performing column chromatography purification to obtain 270mg of target compound 11, 20-dicarbonyl economic oridonin, wherein the yield is 74%.1H NMR(400MHz,DMSO-d6)δ6.14(s,1H),6.08(d,J=2.9Hz,1H),5.79(s,1H),4.79(dd,J=3.9,1.7Hz,1H),3.74–3.71(m,1H),3.10(d,J=8.3Hz,1H),2.96(s,1H),2.92–2.83(m,2H),2.66(dd,J=16.3,8.4Hz,1H),2.55(s,1H),1.76(ddd,J=14.4,7.6,4.0Hz,1H),1.59(dp,J=12.6,5.1,4.3Hz,2H),1.36(d,J=11.6Hz,2H),1.09(td,J=11.4,10.0,5.2Hz,1H),0.98(td,J=14.0,4.4Hz,1H),0.81(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ204.50,200.41,174.32,148.15,121.28,72.87,70.54,58.52,57.72,46.51,45.35,42.97,41.08,33.81,30.56,28.28,23.36,19.10,18.21.HR-MS(ESI):Calculated for C20H24O5.[M+H]+:345.1702,found:345.1688.
Example 2:
Figure BDA0002962842810000041
compound 1a
Weighing 200mg of 11, 20-dicarbonyl economic oridonin, completely dissolving the oridonin in 10mL of dichloromethane, adding 92mg of benzoic acid under stirring, and sequentially adding 144mg of catalyst 1- (3-dimethylaminopropyl) -3-ethylcarbodiimide hydrochloride (EDCI) and 9mg of 4-Dimethylaminopyridine (DMAP). Monitoring the reaction by a thin layer chromatography plate, adding 30mL of dichloromethane to dilute the reaction system, washing the reaction system with saturated sodium bicarbonate solution for three times, combining water layers, performing back extraction once, combining organic phases, drying with anhydrous sodium sulfate, concentrating, and performing column chromatography purification to obtain a white solid product with yield85%。1H NMR(400MHz,DMSO-d6)δ7.62(d,J=7.8Hz,2H),7.44(d,J=7.5Hz,1H),7.29(t,J=7.5Hz,2H),6.04(s,1H),5.68(s,1H),4.79(s,1H),4.60(d,J=3.5Hz,1H),3.10(s,2H),3.07(s,1H),2.66(d,J=13.8Hz,2H),2.59(t,J=8.3Hz,1H),2.26(s,1H),1.60–1.53(m,1H),1.46–1.36(m,2H),1.14(d,J=11.8Hz,2H),0.86(d,J=8.2Hz,1H),0.57(s,3H),0.47(s,3H).13C NMR(101MHz,DMSO-d6)δ203.35,198.48,173.92,146.12,134.03,129.26,128.93,128.34,122.99,74.02,72.56,58.91,56.40,46.55,45.35,43.21,38.58,33.83,30.50,28.17,23.16,18.94,18.16.HR-MS(ESI):Calculated for C27H28O6.[M+NH4]+:466.2230.found:466.2227.
Example 3:
Figure BDA0002962842810000042
compound 2a
The same operation as in example 2 was carried out using 115mg of 2-methoxybenzoic acid in place of benzoic acid to give a white solid product in a yield of 47%.1H NMR(400MHz,DMSO-d6)δ7.61(dd,J=7.9,1.8Hz,1H),7.58–7.55(m,1H),7.16–7.13(m,1H),7.04–7.01(m,1H),6.25(s,1H),5.91(s,1H),4.99(d,J=1.1Hz,1H),4.83(dd,J=4.1,1.8Hz,1H),3.77(d,J=2.5Hz,3H),3.46(d,J=8.4Hz,1H),3.28(s,1H),2.92(ddd,J=13.1,8.0,2.6Hz,2H),2.81(d,J=8.2Hz,1H),2.71(d,J=16.4Hz,1H),1.89–1.84(m,1H),1.69–1.65(m,1H),1.41(d,J=3.9Hz,1H),1.37(s,1H),1.23(s,1H),1.11(d,J=3.8Hz,1H),1.09–1.07(m,1H),0.83(s,3H),0.73(s,3H).13C NMR(101MHz,DMSO-d6)δ203.48,198.47,174.02,164.49,158.56,146.22,134.56,131.10,122.73,120.25,118.25,112.78,73.80,72.65,58.81,56.30,55.71,46.55,45.32,43.16,39.76,38.55,33.83,30.49,28.16,23.13,18.97,18.15.HR-MS(ESI):Calculated for C28H30O7.[M+NH4]+:496.2335.found:496.2328.
Example 4
Figure BDA0002962842810000051
Compound 2b
The same procedures used in example 2 were repeated except for using 115mg of 3-methoxybenzoic acid in place of benzoic acid to give a white solid product in a yield of 75%.1H NMR(400MHz,DMSO-d6)δ7.44(q,J=2.1,1.6Hz,2H),7.33(t,J=2.1Hz,1H),7.29–7.26(m,1H),6.29(s,1H),5.92(s,1H),5.03(d,J=5.3Hz,1H),4.84–4.80(m,1H),3.80(s,1H),3.30(s,1H),2.92(dt,J=3.9,2.0Hz,1H),2.88(d,J=5.6Hz,1H),2.82(d,J=8.2Hz,1H),2.72(d,J=16.4Hz,1H),1.85–1.80(m,1H),1.68(dd,J=10.5,7.5Hz,1H),1.40(s,1H),1.37(s,1H),1.24(d,J=11.1Hz,1H),1.11(d,J=3.2Hz,1H),1.08(d,J=4.3Hz,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.39,198.47,173.97,164.13,159.29,146.07,130.20,129.64,121.39,119.62,114.32,74.06,72.58,58.89,56.41,55.33,46.52,45.33,43.20,39.73,38.57,33.82,30.48,28.16,23.16,18.93,18.14.HR-MS(ESI):Calculated for C28H30O7.[M+NH4]+:496.2335.found:496.2336.
Example 5
Figure BDA0002962842810000052
Compound 2c
The same procedures used in example 2 were repeated except for using 115mg of 4-methoxybenzoic acid in place of benzoic acid to give a white solid product in a yield of 63%.1H NMR(400MHz,DMSO-d6)δ7.81(d,J=8.8Hz,2H),7.06(d,J=8.7Hz,2H),6.27(s,1H),5.92(s,1H),4.98(s,1H),4.83–4.79(m,1H),3.47(d,J=8.0Hz,1H),3.33(s,3H),2.90(d,J=14.1Hz,2H),2.81(d,J=8.3Hz,1H),2.71(d,J=16.4Hz,1H),1.85–1.79(m,1H),1.73–1.62(m,2H),1.59(d,J=14.0Hz,1H),1.40(s,1H),1.37(s,1H),1.12(d,J=12.5Hz,1H),1.09–1.04(m,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.42,198.57,173.93,163.70,146.21,131.47,122.91,120.43,114.25,73.62,72.58,58.87,56.38,55.59,46.54,45.33,43.19,38.62,33.84,30.51,28.17,23.16,18.95,18.15.HR-MS(ESI):Calculated for C28H30O7.[M+NH4]+:496.2335.found:496.2331.
Example 6
Figure BDA0002962842810000061
Compound 2d
The same procedure as in example 2 was repeated except for using 137mg of 2, 3-dimethoxybenzoic acid in place of the benzoic acid to give a white solid as a product in a yield of 63%.1H NMR(400MHz,DMSO-d6)δ7.30(dd,J=5.8,3.9Hz,1H),7.18–7.15(m,2H),6.26(s,1H),5.94(s,1H),5.05(d,J=1.2Hz,1H),4.79(dt,J=4.5,2.2Hz,1H),3.83(s,3H),3.64(d,J=3.9Hz,3H),3.48(d,J=8.1Hz,1H),3.30(s,1H),2.94–2.88(m,2H),2.82(d,J=8.3Hz,1H),2.72(d,J=16.5Hz,1H),1.87–1.81(m,1H),1.67(d,J=3.0Hz,1H),1.40(d,J=4.6Hz,1H),1.37(s,1H),1.26(s,1H),1.11(d,J=3.9Hz,1H),1.08(d,J=4.5Hz,1H),0.82(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.39,198.53,173.97,164.47,153.14,148.02,146.20,124.35,124.10,122.95,121.58,117.18,74.11,72.62,60.75,58.89,56.30,56.02,46.57,45.30,43.17,39.75,38.58,33.82,30.49,28.15,23.12,18.96,18.14.HR-MS(ESI):Calculated for C29H32O8.[M+NH4]+:526.2441.found:526.2435.
Example 7
Figure BDA0002962842810000071
Compound 2e
The same procedure as in example 2 was repeated except for using 137mg of 3, 4-dimethoxybenzoic acid in place of the benzoic acid to give a white solid as a product in 41% yield.1H NMR(400MHz,DMSO-d6)δ7.45(dd,J=8.4,2.0Hz,1H),7.34(d,J=2.1Hz,1H),7.07(d,J=8.6Hz,1H),6.28(s,1H),5.92(s,1H),4.99(d,J=1.3Hz,1H),4.83–4.80(m,1H),3.83(s,3H),3.78(s,3H),3.46(d,J=2.0Hz,1H),3.30(s,1H),2.92(s,1H),2.88(s,1H),2.86(s,1H),2.75–2.72(m,1H),1.85–1.80(m,1H),1.68(dd,J=10.5,7.6Hz,1H),1.38(s,1H),1.23(s,1H),1.09(d,J=2.2Hz,1H),1.05(d,J=2.2Hz,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.43,198.56,173.93,162.28,154.44,148.81,148.54,124.98,120.36,120.06,112.22,111.44,73.71,72.59,58.85,56.41,55.92,55.63,46.53,45.35,43.20,40.00,38.64,33.84,30.51,28.17,23.18,18.95,18.15.HR-MS(ESI):Calculated for C29H32O8.[M+NH4]+:526.2441.found:526.2440.
Example 8
Figure BDA0002962842810000072
Compound 2f
The same procedure as in example 2 was repeated except for using 160mg of 3,4, 5-trimethoxybenzoic acid in place of benzoic acid to give a white solid as a product in 82% yield.1H NMR(400MHz,DMSO-d6)δ7.11(s,2H),6.29(s,1H),5.94–5.91(m,1H),5.00(d,J=1.2Hz,1H),4.85(dd,J=4.1,1.7Hz,1H),3.80(s,6H),3.74(d,J=2.0Hz,3H),3.31(s,1H),2.92(dd,J=4.2,1.8Hz,1H),2.89(s,1H),2.82(d,J=8.2Hz,1H),2.73(d,J=16.4Hz,1H),1.82(dq,J=11.4,3.6Hz,1H),1.71–1.66(m,1H),1.40(s,1H),1.37(s,1H),1.25(d,J=10.6Hz,2H),1.11(s,1H),1.08(d,J=4.0Hz,1H),0.82(s,3H),0.72(d,J=3.6Hz,3H).13C NMR(101MHz,DMSO-d6)δ203.45,198.47,174.00,163.92,152.77,146.12,142.53,123.32,122.94,106.74,74.10,72.58,60.20,58.85,56.42,56.00,46.50,45.32,43.20,39.73,38.60,33.82,31.09,30.48,29.77,28.15,23.23,18.94,18.15.HR-MS(ESI):Calculated for C30H34O9.[M+NH4]+:556.2547.found:556.2540.
Example 9
Figure BDA0002962842810000081
Compound 3a
The same operation as in example 2 was carried out using 102mg of 2-methylbenzoic acid instead of benzoic acid to give a product as a white solid in a yield of 64%.1H NMR(400MHz,DMSO-d6)δ7.71(dd,J=7.8,1.5Hz,1H),7.54–7.50(m,1H),7.34(d,J=3.2Hz,1H),7.33(d,J=3.4Hz,1H),6.28(s,1H),5.94(s,1H),5.03(s,1H),4.82–4.78(m,1H),3.51(d,J=8.0Hz,1H),3.31(s,1H),2.92(s,1H),2.90–2.87(m,1H),2.82(d,J=8.3Hz,1H),2.72(d,J=16.4Hz,1H),2.45(s,3H),1.84–1.79(m,1H),1.67(dd,J=10.6,7.6Hz,2H),1.40(d,J=2.1Hz,1H),1.38–1.36(m,1H),1.11(s,1H),1.08(d,J=4.5Hz,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.41,198.58,173.94,165.16,146.29,139.76,132.95,131.87,130.25,127.82,126.21,122.98,73.93,72.60,58.84,56.35,46.51,45.28,43.16,39.95,38.61,33.83,30.51,28.16,23.18,21.21,18.97,18.15.HR-MS(ESI):Calculated for C28H30O6.[M+NH4]+:480.2368.found:480.2379.
Example 10
Figure BDA0002962842810000082
Compound 3b
The same operation as in example 2 was carried out using 102mg of 3-methylbenzoic acid instead of benzoic acid to give the product as a white solid in a yield of 67%.1H NMR(400MHz,DMSO-d6)δ7.68(d,J=1.9Hz,1H),7.65(d,J=8.0Hz,1H),7.51(d,J=7.6Hz,1H),7.42(d,J=3.0Hz,1H),6.28(s,1H),5.92(s,1H),5.01(d,J=1.1Hz,1H),4.87–4.84(m,1H),3.49(d,J=8.0Hz,1H),3.31(s,1H),2.92(dd,J=4.2,1.8Hz,1H),2.88(d,J=6.4Hz,1H),2.82(d,J=8.3Hz,1H),2.72(d,J=16.5Hz,1H),2.36(s,3H),1.82(dq,J=11.4,3.8Hz,1H),1.68(d,J=3.1Hz,1H),1.64–1.57(m,1H),1.40(d,J=2.4Hz,1H),1.38(s,1H),1.11(d,J=3.5Hz,1H),1.09–1.04(m,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.38,198.52,173.94,164.47,146.12,138.42,134.67,129.52,128.82,128.33,126.48,123.01,74.02,72.55,58.92,56.38,46.57,45.35,43.22,38.56,33.84,30.51,28.17,23.18,20.73,18.94,18.15.HR-MS(ESI):Calculated for C28H30O6.[M+NH4]+:480.2368.found:480.2380.
Example 11
Figure BDA0002962842810000091
Compound 3c
The same procedures used in example 2 were repeated except for using 102mg of 4-methylbenzoic acid in place of the benzoic acid to give a product as a white solid in a yield of 36%.1H NMR(400MHz,DMSO-d6)δ7.76(d,J=7.9Hz,2H),7.34(d,J=7.9Hz,2H),6.27(s,1H),5.92(s,1H),5.00(s,1H),4.85–4.80(m,1H),3.49(d,J=8.1Hz,1H),2.92(t,J=12.2Hz,2H),2.82(t,J=8.3Hz,1H),2.71(d,J=16.5Hz,1H),2.38(s,3H),1.86–1.79(m,1H),1.71–1.57(m,2H),1.44–1.36(m,2H),1.31–1.22(m,1H),1.08(dd,J=13.8,9.9Hz,2H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.38,198.53,173.92,164.31,146.15,144.57,129.47(*2),129.31(*2),129.28,129.06,125.61,122.96,73.84,72.56,58.89,56.38,46.55,45.34,43.21,39.75,38.58,33.84,30.51,28.17,23.16,21.19,18.94,18.15.HR-MS(ESI):Calculated for C28H30O6.[M+NH4]+:480.2368.found:480.2381.
Example 12
Figure BDA0002962842810000092
Compound 4a
The same procedures used in example 2 were repeated except for using 118mg of 3-chlorobenzoic acid in place of benzoic acid to give a white solid product in a yield of 56%.1H NMR(400MHz,DMSO-d6)δ7.84–7.81(m,2H),7.79–7.76(m,1H),7.59(d,J=8.0Hz,1H),6.30(s,1H),5.93(s,1H),5.05(s,1H),4.90–4.87(m,1H),3.52(d,J=8.0Hz,1H),3.31(s,1H),2.92(dd,J=4.1,1.7Hz,1H),2.90–2.87(m,1H),2.83(d,J=8.2Hz,1H),2.73(d,J=16.4Hz,1H),1.84–1.78(m,1H),1.71–1.66(m,1H),1.62(t,J=3.6Hz,1H),1.40(s,1H),1.39–1.35(m,1H),1.11(d,J=3.6Hz,1H),1.10–1.07(m,1H),0.83(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.32,198.39,173.97,163.21,145.99,133.84,133.58,130.96,130.40,128.68,128.02,123.14,74.49,72.48,58.98,56.38,46.55,45.33,43.20,39.74,38.51,33.82,30.49,28.15,23.17,18.93,18.15.HR-MS(ESI):Calculated for C27H27ClO6.[M+NH4]+:500.1840.found:500.1839.
Example 13
Figure BDA0002962842810000101
Compound 4b
The same operation as in example 2 was carried out using 118mg of 4-chlorobenzoic acid instead of benzoic acid to give a white solid product in 74% yield.1H NMR(400MHz,DMSO-d6)δ7.87(d,J=8.2Hz,2H),7.61(d,J=8.1Hz,2H),6.28(s,1H),5.93(s,1H),5.03(s,1H),4.85(d,J=3.3Hz,1H),3.51(d,J=8.1Hz,1H),2.92(t,J=12.4Hz,2H),2.83(t,J=8.3Hz,1H),2.72(d,J=16.3Hz,1H),1.80(dq,J=8.3,5.0Hz,1H),1.71–1.57(m,2H),1.44–1.35(m,2H),1.25(d,J=10.4Hz,1H),1.08(dd,J=15.6,11.3Hz,2H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.31,198.40,173.91,163.54,146.04,139.00,131.14(*2),129.12(*2),127.21,123.08,74.28,72.49,58.93,56.38,46.55,45.34,43.20,39.75,38.53,33.83,30.51,28.16,23.15,18.94,18.15.HR-MS(ESI):Calculated for C27H27ClO6.[M+NH4]+:500.1840.found:500.1839.
Example 14
Figure BDA0002962842810000111
Compound 4c
The same procedure as in example 2 was repeated except for using 144mg of 2, 3-dichlorobenzoic acid in place of benzoic acid to give the product as a white solid in a yield of 80%.1H NMR(400MHz,DMSO-d6)δ7.88(dd,J=8.1,1.6Hz,1H),7.70(dd,J=7.8,1.6Hz,1H),7.50(t,J=8.0Hz,1H),6.30–6.25(m,1H),5.99–5.93(m,1H),5.08(d,J=1.2Hz,1H),4.81(dt,J=5.5,2.7Hz,1H),3.57(d,J=8.4Hz,1H),3.32(s,1H),2.93–2.87(m,2H),2.86–2.82(m,1H),2.73(d,J=16.4Hz,1H),1.81(ddd,J=14.6,7.6,4.1Hz,1H),1.69–1.64(m,1H),1.41–1.36(m,2H),1.24(d,J=3.8Hz,1H),1.10(d,J=3.7Hz,1H),1.09–1.04(m,1H),0.81(s,3H),0.72(d,J=2.8Hz,3H).13C NMR(101MHz,DMSO-d6)δ203.19,198.18,173.90,163.25,146.00,133.99,133.20,131.38,129.67,129.55,128.70,123.18,75.23,72.47,58.92,56.32,46.50,45.28,43.17,39.76,38.49,33.82,30.50,28.14,23.13,18.97,18.15.HR-MS(ESI):Calculated for C27H26Cl2O6.[M+NH4]+:534.1450.found:534.1442.
Example 15
Figure BDA0002962842810000112
Compound 4d
The same procedure used in example 2 was repeated except for using 144mg of 2, 6-dichlorobenzoic acid in place of benzoic acid to give the product as a white solid in a yield of 78%.1H NMR(400MHz,DMSO-d6)δ7.59(s,2H),7.58(s,1H),6.26(s,1H),5.99(s,1H),5.08(s,1H),4.75–4.73(m,1H),3.57(d,J=8.3Hz,1H),3.34(s,2H),2.95–2.91(m,1H),2.88(d,J=8.3Hz,1H),2.86–2.80(m,1H),2.75(d,J=16.5Hz,1H),1.87–1.81(m,1H),1.65(t,J=2.9Hz,1H),1.39(d,J=3.6Hz,1H),1.37(s,1H),1.23(s,1H),1.12–1.07(m,2H),0.81(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.09,197.96,173.92,162.83,145.77,132.91,131.48,130.40(*2),128.44(*2),123.42,75.59,72.47,58.89,56.17,46.37,45.25,43.18,39.73,38.46,33.82,30.46,28.12,23.06,18.98,18.12.HR-MS(ESI):Calculated for C27H26Cl2O6.[M+NH4]+:534.1450.found:534.1448.
Example 16
Figure BDA0002962842810000121
Compound 5a
The same procedure as in example 2 was repeated except for using 151mg of 2-bromobenzoic acid in place of benzoic acid to give the product as a white solid in a yield of 71%.1H NMR(400MHz,DMSO-d6)δ7.76(dd,J=5.8,3.4Hz,1H),7.71(dd,J=6.0,3.6Hz,1H),7.51(dd,J=5.9,3.4Hz,2H),6.27(s,1H),5.95(s,1H),5.06(s,1H),4.84(dt,J=4.4,2.2Hz,1H),3.55(d,J=8.2Hz,1H),3.31(s,1H),2.95–2.91(m,1H),2.90–2.87(m,1H),2.84(d,J=8.3Hz,1H),2.73(d,J=16.4Hz,1H),1.83(ddd,J=10.5,7.5,3.7Hz,1H),1.66(dd,J=7.8,2.9Hz,1H),1.40(s,1H),1.38–1.35(m,1H),1.25(d,J=10.6Hz,1H),1.10(d,J=3.2Hz,1H),1.08(d,J=6.6Hz,1H),0.82(s,3H),0.72(d,J=3.0Hz,3H).13C NMR(101MHz,DMSO-d6)δ203.27,198.28,173.94,164.21,146.04,134.11,133.81,131.18,130.77,128.02,123.20,120.21,74.93,72.54,58.95,56.31,46.52,45.28,43.17,39.75,38.51,33.82,30.49,28.14,23.14,18.98,18.15.HR-MS(ESI):Calculated for C27H27BrO6.[M+NH4]+:544.1335.found:544.1334.
Example 17
Figure BDA0002962842810000122
Compound 5b
The same procedure as in example 2 was repeated except for using 151mg of 3-bromobenzoic acid in place of benzoic acid to give the product as a white solid in a yield of 65%.1H NMR(400MHz,DMSO-d6)δ7.94(t,J=1.8Hz,1H),7.92–7.89(m,1H),7.86(dt,J=7.9,1.4Hz,1H),7.51(t,J=7.9Hz,1H),6.29(s,1H),5.93(s,1H),5.05(d,J=1.2Hz,1H),4.88(dd,J=4.0,1.7Hz,1H),3.51(d,J=8.1Hz,1H),3.31(s,1H),2.91(dd,J=4.2,1.8Hz,1H),2.90–2.87(m,1H),2.83(t,J=8.2Hz,1H),2.72(d,J=16.4Hz,1H),1.84–1.78(m,1H),1.68(dd,J=10.5,7.5Hz,1H),1.41(dd,J=7.0,3.0Hz,1H),1.37(s,1H),1.25(d,J=11.1Hz,1H),1.11(d,J=3.4Hz,1H),1.08(t,J=3.9Hz,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.25,197.97,173.95,164.12,163.60,145.82,138.48,129.50,127.21,123.23,116.45,114.64,75.08,72.27,59.01,56.68,56.23,46.42,45.18,43.06,39.80,38.08,33.81,30.51,28.12,23.19,19.02,18.16.HR-MS(ESI):Calculated for C27H27BrO6.[M+H]+:527.1069.found:527.1063.
Example 18
Figure BDA0002962842810000131
Compound 5c
The same procedure used in example 2 was repeated except for using 151mg of 4-bromobenzoic acid in place of benzoic acid to give the product as a white solid in 67% yield.1H NMR(400MHz,DMSO-d6)δ7.77(d,J=3.1Hz,4H),6.28(s,1H),5.93(s,1H),5.03(s,1H),4.86–4.82(m,1H),3.51(d,J=8.1Hz,1H),2.91(t,J=12.4Hz,2H),2.83(t,J=8.3Hz,1H),2.72(d,J=16.4Hz,1H),1.85–1.77(m,1H),1.69(d,J=9.4Hz,1H),1.66–1.59(m,1H),1.43–1.36(m,2H),1.25(d,J=10.0Hz,1H),1.08(dd,J=13.7,9.6Hz,2H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.31,198.40,173.91,163.72,146.04,132.09(*2),131.22(*2),128.18,127.56,123.09,74.29,72.48,58.93,56.38,46.55,45.33,43.20,38.52,33.83,30.51,28.16,23.15,18.94,18.15.HR-MS(ESI):Calculated for C27H27BrO6.[M+H]+:527.1069.found:527.1064.
Example 19
Figure BDA0002962842810000132
Compound 6a
The same procedures used in example 2 were repeated except for using 105mg of 2-fluorobenzoic acid instead of the benzoic acid to give the product as a white solid in a yield of 85%.1H NMR(400MHz,DMSO-d6)δ7.83(td,J=7.6,1.7Hz,1H),7.72(dddd,J=7.9,6.9,5.0,1.9Hz,1H),7.38–7.33(m,2H),6.27(d,J=1.3Hz,1H),5.92(d,J=1.1Hz,1H),5.05(d,J=1.1Hz,1H),4.83–4.79(m,1H),3.53(d,J=8.2Hz,1H),2.94–2.88(m,2H),2.84(t,J=8.3Hz,1H),2.72(d,J=16.4Hz,1H),2.51(d,J=2.0Hz,1H),1.84(ddd,J=10.5,7.5,3.8Hz,1H),1.70–1.66(m,1H),1.60(dt,J=14.2,3.6Hz,1H),1.41(d,J=12.2Hz,1H),1.37(s,1H),1.15–1.10(m,1H),1.09–1.05(m,1H),0.82(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.30,198.29,173.90,162.38,162.13,159.81,146.02,136.10,131.86,124.85,122.97,117.32,116.87,74.40,72.52,58.83,56.32,46.54,45.33,43.21,38.50,33.84,30.49,28.16,23.10,18.94,18.15.HR-MS(ESI):Calculated for C27H27FO6.[M+NH4]+:484.2135.found:484.2131.
Example 20
Figure BDA0002962842810000141
Compound 6b
The same procedures used in example 2 were repeated except for using 105mg of 3-fluorobenzoic acid instead of the benzoic acid to give a white solid product in a yield of 82%.1H NMR(400MHz,DMSO-d6)δ7.72(dt,J=7.2,1.6Hz,1H),7.62(dd,J=5.1,2.7Hz,1H),7.60(q,J=2.0Hz,1H),7.59–7.56(m,1H),6.29(d,J=1.2Hz,1H),5.93(d,J=1.1Hz,1H),5.04(d,J=1.2Hz,1H),4.92–4.88(m,1H),3.52(d,J=8.2Hz,1H),2.92(dd,J=4.1,1.8Hz,1H),2.90–2.87(m,1H),2.86–2.80(m,1H),2.72(d,J=16.5Hz,1H),2.51(d,J=1.9Hz,1H),1.81(ddd,J=14.6,7.5,4.1Hz,1H),1.68(dd,J=10.5,7.5Hz,1H),1.65–1.56(m,1H),1.43–1.39(m,1H),1.37(d,J=3.2Hz,1H),1.12(q,J=4.6,3.8Hz,1H),1.09–1.04(m,1H),0.83(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.30,198.37,173.94,163.30,163.11,160.67,146.02,131.28,130.65,125.55,123.08,121.20,115.96,74.48,72.49,58.96,56.38,46.54,45.35,43.21,38.51,33.83,30.51,28.16,23.16,18.94,18.15.HR-MS(ESI):Calculated for C27H27FO6.[M+NH4]+:484.2135.found:484.2135.
Example 21
Figure BDA0002962842810000151
Compound 6c
The same procedures used in example 2 were repeated except for using 105mg of 4-fluorobenzoic acid instead of the benzoic acid to give a white solid product in a yield of 76%.1H NMR(400MHz,DMSO-d6)δ7.96–7.92(m,2H),7.39–7.35(m,2H),6.28(s,1H),5.92(s,1H),5.02(d,J=1.1Hz,1H),4.88–4.84(m,1H),3.50(d,J=8.2Hz,1H),2.93–2.87(m,2H),2.83(t,J=8.3Hz,1H),2.72(d,J=16.4Hz,1H),2.51(s,1H),1.82(ddd,J=14.5,7.6,4.1Hz,1H),1.68(dd,J=10.5,7.5Hz,1H),1.59(d,J=13.8Hz,1H),1.40(t,J=3.0Hz,1H),1.37(s,1H),1.11(d,J=3.5Hz,1H),1.09–1.04(m,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.34,198.44,173.92,166.72,163.40,146.08,132.36,132.26,132.10,124.95,123.04,116.24,116.02,115.68,115.46,74.16,72.51,58.92,56.38,46.54,45.34,43.21,38.55,33.83,30.51,28.16,23.15,18.94,18.15.HR-MS(ESI):Calculated for C27H27FO6.[M+NH4]+:484.2135.found:484.2131.
Example 22
Figure BDA0002962842810000152
Compound 6d
The same procedures used in example 2 were repeated except for using 133mg of 2,3, 4-trifluorobenzoic acid in place of the benzoic acid to give the product as a white solid in a yield of 76%.1H NMR(400MHz,DMSO-d6)δ7.72(tdd,J=8.2,5.8,2.3Hz,1H),7.51–7.44(m,1H),6.27(s,1H),5.93(s,1H),5.07(s,1H),4.83–4.80(m,1H),3.53(d,J=8.1Hz,1H),3.33(s,1H),2.93–2.89(m,1H),2.87(d,J=3.9Hz,1H),2.84(t,J=8.2Hz,1H),2.72(d,J=16.4Hz,1H),1.82(ddd,J=14.5,7.5,4.1Hz,1H),1.65(s,1H),1.60(td,J=10.4,5.2Hz,1H),1.41(dd,J=5.8,2.4Hz,1H),1.37(s,1H),1.15–1.10(m,1H),1.09–1.04(m,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.25,198.16,173.90,160.65,145.90,126.91,126.87,126.82,126.78,123.09,113.25,113.11,74.80,72.43,58.84,56.33,46.52,45.30,43.18,38.46,33.83,30.49,28.13,23.10,18.93,18.14.HR-MS(ESI):Calculated for C27H25F3O6.[M+NH4]+:520.1947.found:520.1905.
Example 23
Figure BDA0002962842810000161
Compound 6e
The same procedure used in example 2 was repeated except for using 160mg of 2,3,4,5, 6-pentafluorobenzoic acid in place of benzoic acid to give a white solid as a product in 54% yield.1H NMR(400MHz,DMSO-d6)δ6.27(s,1H),5.98–5.93(m,1H),5.14(s,1H),4.75(dt,J=5.8,2.9Hz,1H),3.54(d,J=8.1Hz,1H),2.92–2.83(m,3H),2.72(d,J=16.5Hz,1H),1.86–1.80(m,1H),1.67(dd,J=10.6,7.5Hz,1H),1.63–1.54(m,1H),1.43–1.39(m,1H),1.37(s,1H),1.10(d,J=3.4Hz,1H),1.09–1.04(m,1H),0.82(s,3H),0.72(d,J=2.8Hz,3H).13C NMR(101MHz,DMSO-d6)δ203.03,197.89,173.82,145.72,123.20,75.73,72.32,58.84,56.31,46.50,45.28,43.19,38.48,33.83,30.47,28.12,23.04,18.92,18.14.HR-MS(ESI):Calculated for C27H23F5O6.[M+NH4]+:556.1759.found:556.1754.
Example 24
Figure BDA0002962842810000162
Compound 7a
The same procedures used in example 2 were repeated except for using 143mg of 2-trifluoromethylbenzoic acid instead of benzoic acid to obtain a white solid product with a yield of 48%.1H NMR(400MHz,DMSO-d6)δ7.89(dd,J=6.5,3.3Hz,1H),7.82(s,1H),7.82(s,1H),7.80(d,J=3.5Hz,1H),6.27(s,1H),5.96(s,1H),5.06(d,J=1.1Hz,1H),4.74(q,J=1.8Hz,1H),3.53(d,J=8.2Hz,1H),3.33(s,1H),2.92(d,J=5.0Hz,1H),2.88(d,J=8.3Hz,1H),2.86–2.82(m,1H),2.74(d,J=16.4Hz,1H),1.84–1.78(m,1H),1.67(dd,J=10.4,7.4Hz,1H),1.60(dt,J=14.3,3.5Hz,1H),1.42–1.39(m,1H),1.37(s,1H),1.10(dd,J=6.7,2.5Hz,1H),1.07(d,J=9.3Hz,1H),0.81(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.18,173.90,164.72,145.87,133.00,132.51,130.28,126.85,126.80,123.08,75.21,72.36,58.95,56.22,46.55,45.25,43.16,38.30,33.81,30.48,28.13,23.10,18.95,18.14.HR-MS(ESI):Calculated for C28H27FO6.[M+NH4]+:534.2103.found:534.2096.
Example 25
Figure BDA0002962842810000171
Compound 7b
The same operation as in example 2 was carried out using 143mg of 3-trifluoromethylbenzoic acid instead of benzoic acid to give the product as a white solid with a yield of 52%.1H NMR(400MHz,DMSO-d6)δ8.15(d,J=7.9Hz,1H),8.10–8.06(m,2H),7.80(t,J=8.1Hz,1H),6.30(s,1H),5.93(s,1H),5.10(s,1H),4.92–4.87(m,1H),3.54(d,J=8.1Hz,1H),2.95–2.88(m,2H),2.87–2.81(m,1H),2.73(d,J=16.4Hz,1H),1.81(ddd,J=14.5,7.5,4.1Hz,1H),1.69(dd,J=10.6,7.6Hz,1H),1.66–1.57(m,1H),1.42(d,J=12.3Hz,1H),1.36(d,J=12.5Hz,1H),1.25(d,J=11.4Hz,1H),1.16–1.11(m,1H),1.10–1.05(m,1H),0.83(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.27,198.35,173.93,163.19,146.05,133.26,130.44,129.59,125.54,125.50,123.08,74.60,72.45,58.99,56.43,46.57,45.34,43.21,38.54,33.83,30.50,28.16,23.18,18.94,18.16.HR-MS(ESI):Calculated for C28H27FO6.[M+NH4]+:534.2103.found:534.2097.
Example 26
Figure BDA0002962842810000181
Compound 7c
The same operation as in example 2 was carried out using 143mg of 4-trifluoromethylbenzoic acid instead of benzoic acid to give the product as a white solid in a yield of 67%.1H NMR(400MHz,DMSO-d6)δ8.07(d,J=8.2Hz,2H),7.92(d,J=8.3Hz,2H),6.30(s,1H),5.94(s,1H),5.10(s,1H),4.90–4.86(m,1H),3.55(d,J=8.1Hz,1H),3.33(s,1H),2.95–2.89(m,2H),2.85(d,J=8.2Hz,1H),2.76(s,1H),1.85–1.79(m,1H),1.72–1.67(m,1H),1.63–1.59(m,1H),1.39(d,J=12.6Hz,2H),1.12(dt,J=8.4,5.2Hz,2H),0.83(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.27,173.93,163.31,145.97,132.15,130.18,125.91,125.88,125.84,123.13,74.57,72.48,58.98,56.42,46.56,45.34,43.21,39.74,38.52,33.81,30.47,28.15,23.14,18.92,18.14.HR-MS(ESI):Calculated for C28H27FO6.[M+NH4]+:534.2103.found:534.2100.
Example 27
Figure BDA0002962842810000182
Compound 8a
The same procedure used in example 2 was repeated except for using 126mg of 2-nitrobenzoic acid in place of benzoic acid to give the product as a white solid in 85% yield.1H NMR(400MHz,DMSO-d6)δ8.10–8.07(m,1H),7.87(d,J=3.7Hz,1H),7.86–7.85(m,1H),7.84(s,1H),6.25(s,1H),5.95(s,1H),5.06(s,1H),4.74–4.71(m,1H),3.54(d,J=8.3Hz,1H),3.30(s,1H),2.93–2.86(m,2H),2.85–2.82(m,1H),2.73(d,J=16.4Hz,1H),1.83–1.77(m,1H),1.65(d,J=3.0Hz,1H),1.40(d,J=4.3Hz,1H),1.38–1.36(m,1H),1.23(s,1H),1.10(d,J=3.6Hz,1H),1.07(d,J=4.5Hz,1H),0.81(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.23,197.93,173.96,163.53,147.28,145.68,133.92,133.31,129.93,125.11,124.26,123.32,75.25,72.34,58.99,56.26,46.45,45.21,43.11,39.75,38.19,33.80,30.48,28.10,23.12,18.97,18.13.HR-MS(ESI):Calculated for C27H27NO8.[M+NH4]+:511.2080.found:511.2077.
Example 28
Figure BDA0002962842810000191
Compound 8b
The same procedure as in example 2 was repeated except for using 126mg of 3-nitrobenzoic acid in place of the benzoic acid to give a white solid product in a yield of 79%.1H NMR(400MHz,DMSO-d6)δ8.51(d,J=8.2Hz,2H),8.29–8.25(m,1H),7.85(t,J=7.9Hz,1H),6.31(s,1H),5.95(s,1H),5.12(s,1H),4.91–4.88(m,1H),3.56(d,J=8.1Hz,1H),3.33(s,1H),2.92(q,J=1.9Hz,1H),2.89(d,J=2.6Hz,1H),2.88–2.83(m,1H),2.74(d,J=16.5Hz,1H),1.84–1.78(m,1H),1.69(dd,J=10.5,7.5Hz,1H),1.60(dt,J=12.3,2.7Hz,1H),1.43–1.40(m,1H),1.38(s,1H),1.12(d,J=3.9Hz,1H),1.09(t,J=4.8Hz,1H),0.83(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.30,198.32,173.97,162.74,147.88,145.93,135.33,130.84,129.97,128.30,123.71,123.25,74.79,72.44,58.99,56.43,46.57,45.31,43.19,39.74,38.52,33.82,30.49,28.14,23.16,18.93,18.14.HR-MS(ESI):Calculated for C27H27NO8.[M+NH4]+:511.2080.found:511.2086.
Example 29
Figure BDA0002962842810000192
Compound 8c
The same procedure as in example 2 was repeated except for using 126mg of 4-nitrobenzoic acid in place of the benzoic acid to give a white solid product in a yield of 71%.1H NMR(400MHz,DMSO-d6)δ8.35(d,J=2.1Hz,1H),8.33(d,J=2.4Hz,1H),8.11(d,J=2.3Hz,1H),8.09(q,J=2.2Hz,1H),6.30(s,1H),5.94(s,1H),5.09(s,1H),4.91–4.87(m,1H),3.56(d,J=8.2Hz,1H),3.33(s,1H),2.92(q,J=1.9Hz,1H),2.89(s,1H),2.84(d,J=8.2Hz,1H),2.74(d,J=16.5Hz,1H),1.85–1.79(m,1H),1.69(dd,J=10.5,7.4Hz,1H),1.60(dt,J=14.2,3.7Hz,1H),1.41(s,1H),1.39–1.36(m,1H),1.12(d,J=4.0Hz,1H),1.09(d,J=4.6Hz,1H),0.83(s,3H),0.72(d,J=3.8Hz,3H).13C NMR(101MHz,DMSO-d6)δ203.29,198.30,173.96,162.98,150.52,145.89,133.77,130.82(*2),123.95(*2),123.26,74.83,72.46,59.00,56.41,46.56,45.32,43.20,39.73,38.48,33.82,30.48,28.14,23.14,18.93,18.14.HR-MS(ESI):Calculated for C27H27NO8.[M+NH4]+:511.2080.found:511.2079.
Example 30
Figure BDA0002962842810000201
Compound 8d
The same procedure used in example 2 was repeated except for using 160mg of 2, 4-dinitrobenzoic acid in place of benzoic acid to give a white solid product in a yield of 64%.1H NMR(400MHz,DMSO-d6)δ8.81(dd,J=4.3,2.2Hz,1H),8.64(ddd,J=8.0,5.7,2.2Hz,1H),8.14(d,J=8.5Hz,1H),6.25(d,J=1.2Hz,1H),5.96(d,J=1.2Hz,1H),5.11(d,J=1.2Hz,1H),4.75(dd,J=3.9,1.7Hz,1H),3.62–3.56(m,1H),2.89(d,J=8.7Hz,1H),2.87–2.84(m,1H),2.74(d,J=16.5Hz,1H),1.84–1.73(m,2H),1.64(dt,J=10.4,6.5Hz,2H),1.39(s,1H),1.37(s,1H),1.23(s,1H),1.12–1.09(m,1H),1.08–1.05(m,1H),0.81(s,3H),0.73(s,3H).13C NMR(101MHz,DMSO-d6)δ203.09,197.76,173.90,162.36,149.20,147.10,145.60,131.62,130.11,128.50,123.43,119.90,75.94,72.24,59.04,56.30,46.45,45.22,43.12,39.78,38.18,33.82,30.50,28.11,23.12,18.99,18.15.HR-MS(ESI):Calculated for C27H26N2O10.[M+NH4]+:556.1931.found:556.1926.
Example 31
Figure BDA0002962842810000202
Compound 8e
The same procedure used in example 2 was repeated except for using 160mg of 3, 4-dinitrobenzoic acid instead of benzoic acid to give a white solid product in 56% yield.1H NMR(400MHz,DMSO-d6)δ8.54(d,J=3.0Hz,1H),8.35(d,J=4.1Hz,2H),6.30(s,1H),5.93(d,J=5.6Hz,1H),5.10(s,1H),4.99–4.95(m,1H),3.56(d,J=8.1Hz,1H),2.92(d,J=3.8Hz,1H),2.89(dd,J=5.7,2.3Hz,1H),2.86–2.82(m,1H),2.73(d,J=16.5Hz,1H),1.82–1.76(m,1H),1.72–1.67(m,1H),1.42–1.40(m,1H),1.38(s,1H),1.25(d,J=10.7Hz,1H),1.11(d,J=4.3Hz,1H),1.09(t,J=4.1Hz,1H),0.83(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.19,173.96,145.83,141.75,135.24,133.51,126.34,126.22,123.31,75.52,72.30,59.12,56.40,46.61,45.36,43.22,38.40,33.83,30.51,28.15,23.15,18.94,18.15.HR-MS(ESI):Calculated for C27H26N2O10.[M+H]+:539.1666.found:539.1652.
Example 32
Figure BDA0002962842810000211
Compound 8f
The same procedure used in example 2 was repeated except for using 160mg of 3, 5-dinitrobenzoic acid in place of benzoic acid to give a white solid product in 74% yield.1H NMR(400MHz,DMSO-d6)δ9.06–9.02(m,1H),8.78(d,J=2.1Hz,2H),6.33(s,1H),5.96(s,1H),5.18(s,1H),4.96–4.92(m,1H),3.58(d,J=8.1Hz,1H),3.34(s,1H),2.91(d,J=3.9Hz,1H),2.90–2.84(m,2H),2.75(d,J=16.5Hz,1H),1.81(ddd,J=11.0,7.6,3.8Hz,1H),1.72–1.68(m,1H),1.39(d,J=12.7Hz,2H),1.25(d,J=10.2Hz,1H),1.12(s,1H),1.10–1.08(m,1H),0.83(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.18,198.18,173.92,161.36,148.26(*2),145.90,131.51,128.98(*2),123.36,122.92,75.48,72.29,59.06,56.48,46.60,45.30,43.19,39.76,38.51,33.84,30.51,28.14,23.17,18.94,18.16.HR-MS(ESI):Calculated for C27H26N2O10.[M+NH4]+:556.1931.found:556.1921.
Example 33
Figure BDA0002962842810000221
Compound 8j
The same procedure used in example 2 was repeated except for using 149mg of 2-nitro-5-methoxybenzoic acid in place of benzoic acid to give a white solid product in a yield of 69%.1H NMR(400MHz,DMSO-d6)δ8.17–8.14(m,1H),7.30(d,J=3.3Hz,1H),7.29–7.27(m,1H),6.23(s,1H),5.94(d,J=1.1Hz,1H),5.07(d,J=1.2Hz,1H),4.74(dd,J=3.9,1.7Hz,1H),3.94(d,J=8.8Hz,1H),3.92(s,3H),3.58(d,J=8.4Hz,1H),3.30(s,1H),2.90–2.86(m,1H),2.86–2.82(m,1H),2.74(d,J=16.4Hz,1H),1.81–1.75(m,1H),1.67–1.61(m,2H),1.40(d,J=3.8Hz,1H),1.37(s,1H),1.09(d,J=4.2Hz,1H),1.06(d,J=4.4Hz,1H),0.81(s,3H),0.73(s,3H).13C NMR(101MHz,DMSO-d6)δ203.15,197.86,173.94,145.68,127.85,127.75,123.35,119.55,117.24,116.98,75.54,72.23,59.05,56.25,46.44,45.2,43.10,39.79,38.12,33.81,30.51,28.12,23.15,19.00,18.15.HR-MS(ESI):Calculated for C28H29NO9.[M+H]+:524.1921.found:524.1906.
Example 34
Figure BDA0002962842810000222
Compound 8h
The same operation as in example 2 was carried out using 137mg of 2-nitro-5-methylbenzoic acid instead of benzoic acid to give the product as a white solid in a yield of 78%.1H NMR(400MHz,DMSO-d6)δ8.04–7.99(m,1H),7.62(d,J=7.0Hz,2H),6.24(s,1H),5.95(s,1H),5.05(s,1H),4.73(d,J=3.9Hz,1H),3.53(d,J=8.7Hz,1H),3.30(s,1H),2.89(d,J=7.7Hz,1H),2.85(d,J=7.7Hz,1H),2.76–2.70(m,1H),2.45(s,3H),1.82–1.76(m,1H),1.64(dt,J=11.3,5.7Hz,2H),1.40(s,1H),1.11–1.06(m,2H),0.81(s,3H),0.73(s,3H).13C NMR(101MHz,DMSO-d6)δ203.18,197.96,173.91,164.07,145.75,145.54,144.52,132.99,129.75,126.01,124.40,123.25,75.15,72.29,59.01,56.23,46.48,45.24,43.12,38.15,33.82,30.50,28.13,23.15,20.73,18.99,18.15.HR-MS(ESI):Calculated for C28H29NO8.[M+NH4]+:525.2237.found:525.2233.
Example 35
Figure BDA0002962842810000231
Compound 8i
The same procedure used in example 2 was repeated except for using 152mg of 2-nitro-5-chlorobenzoic acid in place of the benzoic acid to give a white solid product in a yield of 70%.1H NMR(400MHz,DMSO-d6)δ8.15(d,J=8.7Hz,1H),7.98(d,J=2.3Hz,1H),7.92(dd,J=8.7,2.3Hz,1H),6.25(s,1H),5.96(s,1H),5.07(s,1H),4.81–4.77(m,1H),3.56(d,J=8.1Hz,1H),3.30(s,1H),2.93–2.81(m,3H),2.74(d,J=16.4Hz,1H),1.78(ddd,J=14.6,7.6,4.0Hz,1H),1.65(dd,J=10.6,7.6Hz,1H),1.43–1.35(m,2H),1.31–1.21(m,1H),1.12(dd,J=13.6,4.1Hz,1H),1.05(dd,J=13.8,4.4Hz,1H),0.81(s,3H),0.73(s,3H).13C NMR(101MHz,DMSO-d6)δ203.15,197.85,173.93,162.59,145.69,145.23,138.88,132.71,129.42,126.40,123.34,75.58,72.21,59.05,56.25,46.44,45.19,43.07,39.79,38.10,33.81,30.50,28.11,23.16,18.99,18.15.HR-MS(ESI):Calculated for C27H26ClNO8.[M+NH4]+:545.1691.found:545.1683.
Example 36
Figure BDA0002962842810000232
Compound 8g
The procedure of example 2 was repeated except for using 140mg of 2-nitro-5-fluorobenzoic acid instead of benzoic acid to give a white solid product in the yield of66%。1H NMR(400MHz,DMSO-d6)δ8.24(dd,J=9.0,4.6Hz,1H),7.81(dd,J=8.2,2.9Hz,1H),7.70(ddd,J=9.0,7.8,2.8Hz,1H),6.25(d,J=1.3Hz,1H),5.95(d,J=1.2Hz,1H),5.07(d,J=1.2Hz,1H),4.78(dt,J=4.1,2.2Hz,1H),3.59–3.53(m,1H),3.30(s,1H),2.92–2.88(m,1H),2.86–2.83(m,1H),2.74(d,J=16.5Hz,1H),1.77(ddd,J=13.4,6.7,2.6Hz,1H),1.68–1.60(m,2H),1.43–1.40(m,1H),1.37(d,J=2.6Hz,1H),1.25(d,J=11.1Hz,1H),1.10(d,J=4.0Hz,1H),1.07(d,J=4.2Hz,1H),0.81(s,3H),0.73(s,3H).13C NMR(101MHz,DMSO-d6)δ203.29,198.40,173.95,163.12,146.04,136.74,131.55,131.18,130.62,128.39,123.12,121.91,74.51,72.48,58.99,56.40,46.57,45.36,43.22,38.53,33.84,30.52,28.17,23.19,18.96,18.17.HR-MS(ESI):Calculated for C27H26FNO8.[M+NH4]+:529.1986.found:529.1934.
Example 37
Figure BDA0002962842810000241
Compound 8k
The same procedures used in example 2 were repeated except for using 140mg of 3-nitro-4-fluorobenzoic acid in place of the benzoic acid to give a white solid product in a yield of 54%.1H NMR(400MHz,DMSO-d6)δ8.48(dd,J=7.1,2.3Hz,1H),8.25(ddd,J=8.8,4.2,2.3Hz,1H),7.75(dd,J=10.9,8.8Hz,1H),6.30(s,1H),5.97–5.91(m,1H),5.08(d,J=1.2Hz,1H),4.94–4.89(m,1H),3.54(d,J=8.1Hz,1H),2.96–2.87(m,2H),2.87–2.81(m,1H),2.73(d,J=16.5Hz,1H),1.80(ddd,J=14.5,7.5,4.1Hz,1H),1.69(dd,J=10.5,7.4Hz,1H),1.65–1.56(m,1H),1.41(d,J=8.3Hz,1H),1.39–1.35(m,1H),1.15–1.10(m,1H),1.10–1.04(m,1H),0.83(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.22,198.26,173.92,162.04,145.93,137.14,137.06,137.01,136.90,127.41,125.54,123.21,119.61,119.39,74.95,72.38,59.02,56.41,46.57,45.35,43.22,38.50,33.83,30.51,28.15,23.15,18.94,18.15.HR-MS(ESI):Calculated for C27H26FNO8.[M+NH4]+:529.1986.found:529.1980.
Example 38
Figure BDA0002962842810000251
Compound 9a
The same procedure as in example 2 was repeated except for using 187mg of 2-iodobenzoic acid in place of the benzoic acid to give a product as a white solid in a yield of 76%.1H NMR(400MHz,DMSO-d6)δ7.79(d,J=7.8Hz,1H),7.39(dd,J=7.8,1.8Hz,1H),7.28(t,J=7.6Hz,1H),7.09–7.05(m,1H),6.04(s,1H),5.72(s,1H),4.81(s,1H),4.63–4.60(m,1H),3.31(d,J=8.2Hz,1H),3.07(s,1H),2.70–2.64(m,2H),2.61(d,J=8.2Hz,1H),2.50(d,J=16.4Hz,1H),1.58(ddd,J=14.7,7.6,4.1Hz,1H),1.45–1.41(m,1H),1.17(d,J=11.4Hz,1H),1.15–1.11(m,1H),1.01(d,J=10.3Hz,1H),0.91–0.86(m,1H),0.85–0.80(m,1H),0.58(s,3H),0.49(d,J=3.3Hz,3H).13C NMR(101MHz,DMSO-d6)δ203.31,198.29,173.98,164.96,145.98,140.81,134.10,133.53,130.43,128.40,123.33,94.27,74.82,72.56,58.97,56.31,46.49,45.26,43.16,39.74,38.51,33.82,30.49,28.13,23.15,18.98,18.14.HR-MS(ESI):Calculated for C27H27IO6.[M+NH4]+:592.1196.found:592.1192.
Example 39
Figure BDA0002962842810000252
Compound 9b
The same procedure as in example 2 was repeated except for using 187mg of 3-iodobenzoic acid in place of the benzoic acid to obtain a white solid product in a yield of 82%.1H NMR(400MHz,DMSO-d6)δ8.11(t,J=1.7Hz,1H),8.06(dt,J=7.9,1.3Hz,1H),7.86(dq,J=8.0,2.2,1.8Hz,1H),7.34(t,J=7.9Hz,1H),6.29(s,1H),5.93(s,1H),5.04(d,J=1.2Hz,1H),4.88–4.84(m,1H),3.50(d,J=8.2Hz,1H),3.31(s,1H),2.94–2.86(m,2H),2.83(t,J=8.2Hz,1H),2.72(d,J=16.4Hz,1H),1.81(ddd,J=14.4,7.5,4.0Hz,1H),1.68(dd,J=10.5,7.5Hz,1H),1.40(s,1H),1.37(s,1H),1.25(d,J=10.6Hz,1H),1.15–1.10(m,1H),1.09–1.04(m,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.31,198.41,173.94,163.05,146.04,142.49,137.31,131.01,130.43,128.63,123.11,94.90,74.40,72.47,58.96,56.39,46.56,45.33,43.20,38.52,33.83,30.51,28.16,23.18,18.95,18.15.HR-MS(ESI):Calculated for C27H27IO6.[M+NH4]+:592.1196.found:592.1191.
Example 40
Figure BDA0002962842810000261
Compound 9c
The same operation as in example 2 was carried out using 187mg of 4-iodobenzoic acid in place of benzoic acid to give the product as a white solid in a yield of 78%.1H NMR(400MHz,DMSO-d6)δ7.95–7.92(m,2H),7.60(dd,J=8.6,2.0Hz,2H),6.28(s,1H),5.92(s,1H),5.03(s,1H),4.83(dd,J=4.0,1.7Hz,1H),3.50(d,J=8.2Hz,1H),3.31(s,1H),2.94–2.90(m,1H),2.88(t,J=3.4Hz,1H),2.83(t,J=8.2Hz,1H),2.72(d,J=16.4Hz,1H),1.82(ddd,J=10.8,7.6,4.0Hz,1H),1.68(dd,J=10.5,7.5Hz,1H),1.42–1.39(m,1H),1.35(d,J=11.4Hz,1H),1.23(s,1H),1.12(q,J=4.8,3.6Hz,1H),1.06(dd,J=13.7,4.5Hz,1H),0.82(s,3H),0.71(s,3H).13C NMR(101MHz,DMSO-d6)δ203.29,198.40,173.90,164.05,146.04,137.94(*2),130.86(*2),127.82,123.07,102.77,74.23,72.49,58.94,56.38,46.56,45.35,43.21,38.53,33.83,30.51,28.16,23.15,18.94,18.15.HR-MS(ESI):Calculated for C27H27IO6.[M+NH4]+:592.1196.found:592.1193.
Example 41
Figure BDA0002962842810000262
Compound 10a
The same procedures used in example 2 were repeated except for using 162mg of 3-bromomethylbenzoic acid in place of the benzoic acid to give a product as a white solid in a yield of 37%.1H NMR(400MHz,DMSO-d6)δ7.96(q,J=2.4,1.8Hz,1H),7.82(dt,J=7.7,1.5Hz,1H),7.78(s,1H),7.56(t,J=7.8Hz,1H),6.28(s,1H),5.92(s,1H),5.03(s,1H),4.87(dd,J=4.1,1.7Hz,1H),3.52(d,J=8.1Hz,1H),3.32(s,1H),2.91(ddd,J=16.2,5.0,2.4Hz,2H),2.84(t,J=8.2Hz,1H),2.72(d,J=16.5Hz,1H),1.83(ddd,J=14.6,7.5,4.1Hz,1H),1.72–1.68(m,1H),1.66–1.61(m,1H),1.40(s,1H),1.37(s,1H),1.25(d,J=9.6Hz,1H),1.12–1.09(m,1H),0.83(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.35,198.48,173.95,164.06,146.07,138.68,134.39,129.45,129.17,128.80,123.08,74.31,72.54,58.99,56.40,46.61,45.39,45.13,43.26,38.54,33.85,30.52,28.18,23.18,18.95,18.16.HR-MS(ESI):Calculated for C28H29BrO6.[M+NH4]+:541.1226.found:541.1210.
Example 42
Figure BDA0002962842810000271
Compound 10b
The same operation as in example 2 was carried out using 162mg of 4-bromomethylbenzoic acid instead of benzoic acid to give the product as a white solid in a yield of 27%.1H NMR(400MHz,DMSO-d6)δ7.78(d,J=8.2Hz,2H),7.49(d,J=8.3Hz,2H),6.28(s,1H),5.92(s,1H),5.03(s,1H),4.87(dd,J=4.1,1.7Hz,1H),3.52(d,J=8.1Hz,1H),3.32(s,1H),2.91(ddd,J=16.2,5.0,2.4Hz,2H),2.84(t,J=8.2Hz,1H),2.72(d,J=16.5Hz,1H),1.83(ddd,J=14.6,7.5,4.1Hz,1H),1.72–1.68(m,1H),1.66–1.61(m,1H),1.40(s,1H),1.37(s,1H),1.25(d,J=9.6Hz,1H),1.12–1.09(m,1H),0.83(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.35,198.48,173.95,164.06,146.07,129.59(*2),128.58(*2),112.89,77.04,72.04,66.09,62.79,61.99,59.14,52.91,46.61,45.39,45.13,43.26,38.54,33.85,30.52,28.18,23.18,18.95,18.16.HR-MS(ESI):Calculated for C28H29BrO6.[M+NH4]+:541.1226.found:541.1230.
Example 43
Figure BDA0002962842810000272
Compound 11a
The benzoic acid was replaced with 116mg of 2-methyl-3-fluorobenzoic acid, and the other operations were performed in the same mannerExample 2 gave a white solid product in 37% yield.1H NMR(400MHz,DMSO-d6)δ7.53(d,J=7.8Hz,1H),7.44(d,J=9.1Hz,1H),7.39–7.34(m,1H),6.29(s,1H),5.95(s,1H),5.05(s,1H),4.82–4.79(m,1H),3.54(d,J=8.1Hz,1H),3.31(s,1H),2.90(dd,J=10.7,6.8Hz,2H),2.83(d,J=8.3Hz,1H),2.73(d,J=16.4Hz,1H),2.41(d,J=2.4Hz,1H),2.34(d,J=2.2Hz,3H),1.82(td,J=7.3,4.0Hz,1H),1.70–1.66(m,1H),1.39(dd,J=14.8,5.8Hz,2H),1.25(d,J=11.2Hz,1H),1.11(d,J=3.1Hz,1H),1.08(d,J=4.6Hz,1H),0.82(s,3H),0.72(s,3H).13C NMR(101MHz,DMSO-d6)δ203.35,198.46,173.95,164.45,161.87,159.46,146.15,130.30,127.57,126.07,123.10,119.69,74.33,72.55,58.88,56.36,46.51,45.28,43.16,39.74,38.55,33.81,30.48,28.15,23.16,18.95,18.14,11.52.HR-MS(ESI):Calculated for C28H29FO6.[M+NH4]+:498.2292.found:498.2285.
Example 44: the anti-tumor activity evaluation of the synthesized jiyuan oridonin derivative on four cells of human breast cancer cells MCF-7, human pancreatic cancer cells SW-1990, human gastric cancer cells MGC-803 and human esophageal cancer cells Ec109 is as follows: the contents are all mass% contents, not specifically stated.
Experimental methods
Taking oridonin as a positive control, selecting the five cancer cells to determine the anti-proliferative activity of the synthesized compound for 72 hours: digesting the cells in logarithmic phase with pancreatin containing 0.25% EDTA to prepare cell suspension with the concentration of 1-10 x 4/mL, inoculating the cells into a 96-well plate according to 1000-10000 cells/well, adding 100 mu L of cell suspension into the fast top wall of each well, and after inoculation is finished, placing the 96-well plate in a position with the volume percentage content of 5% CO2In a 37 ℃ humidity incubator. Discarding supernatant in clean plate after 24h, adding 200 μ L culture solution containing different drug concentrations into each well, arranging three parallel wells according to a certain concentration gradient for each compound, adding 200 μ L blank culture solution into control group, and adding 5 vol% CO2And culturing for 72h in a 37 ℃ humidity incubator. Adding 100 μ L of 30% TCA solution into each well, and fixing at 4 deg.C for 60 min; washing with deionized water for 3-4 times, and air drying;adding 100 μ L of 0.4% SRB per well, and dyeing at room temperature for 30 min; washing with 1% acetic acid for 3 times, and air drying; adding 150 μ L Tris base into each well, shaking with flat shaking table for 15min, measuring absorption density (OD) with microplate reader, and detecting wavelength at 540 nm. Using the solvent control treated cells as a control group, calculating the inhibition rate of the compound on the cells according to the following formula, and calculating the half inhibition concentration IC according to an intermediate effect equation50: inhibition (%) - (control group OD average-administration group OD average)/control group OD average 100%
Anti-tumor activity of oridonin derivative
Figure BDA0002962842810000291
Figure BDA0002962842810000301
Figure BDA0002962842810000311
Ori is oridonin.
aA human breast cancer cell line;bhuman esophageal cancer cell lines;chuman pancreatic cancer cell lines;dhuman gastric cancer cell line.
The experimental results show that the compounds have stronger in-vitro anti-tumor activity and are stronger than the positive control oridonin. Wherein the compound 8i not only has stronger in vitro anti-tumor activity, but also has good selectivity and stronger inhibition effect on SW1990 cell line (IC)500.478 μ M). The compound can be further researched and used for preparing antitumor drugs, is used for clinically treating human esophagus cancer, gastric cancer, pancreatic cancer, colorectal cancer, breast cancer and other diseases, and has potential application value.
Test for stability of drug
According to the guidance principle of stability test of Chinese pharmacopoeia 2020 edition, the stability test is carried out on the 8i with the best activity in the 11, 20-dicarbonyl economic oridonin derivatives. The following tests are required for the starting drug: testing influence factors; accelerating the test; the long-term test results are shown in the following table:
compound 8i influence factor test (1 test batch)
Figure BDA0002962842810000321
Accelerated test and Long-term test of Compound 8i (3 test batches)
Figure BDA0002962842810000322
From the above results it appears that: the compound 8i has better stability and can be further developed and researched.
Drug solubility test
According to solubility test of 'Chinese pharmacopoeia' 2020 edition, the solubility of the series of compounds is determined by taking physiological saline as a solvent, and the result shows that most of the compounds can reach 15mg/mL, and the experimental requirements of animal experiment intravenous injection administration can be met.

Claims (4)

1.11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterification derivative, which is characterized by having a structure shown in a general formula I:
Figure FDA0003611545880000011
r is mono-substituted, di-substituted or polysubstituted, and R is selected from hydrogen; c1-6 straight chain alkyl; c1-6 straight chain alkyl substituted with halogen; a halogen; a nitro group; a methoxy group; a trifluoromethyl group.
2. The 11, 20-dicarbonyl oridonin 14-OH benzoic acid esterified series derivative of claim 1, wherein the R group is hydrogen; a methoxy group; a methyl group; chlorine; bromine; fluorine; a trifluoromethyl group; iodine; a nitro group; a bromomethyl group.
3. The 11, 20-dicarbonyl oridonin 14-OH benzoic acid esterified series derivative of claim 1, selected from the group consisting of:
Figure FDA0003611545880000012
Figure FDA0003611545880000021
Figure FDA0003611545880000031
4. the use of 11, 20-dicarbonyl oridonin 14-O-benzoic acid esterified derivative as defined in claim 1 in the preparation of antitumor medicament, wherein the derivative is used as active component in the preparation of medicament for treating esophageal cancer, gastric cancer, breast cancer or pancreatic cancer.
CN202110242717.7A 2021-03-05 2021-03-05 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof Active CN113004241B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110242717.7A CN113004241B (en) 2021-03-05 2021-03-05 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110242717.7A CN113004241B (en) 2021-03-05 2021-03-05 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof

Publications (2)

Publication Number Publication Date
CN113004241A CN113004241A (en) 2021-06-22
CN113004241B true CN113004241B (en) 2022-07-22

Family

ID=76406017

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110242717.7A Active CN113004241B (en) 2021-03-05 2021-03-05 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN113004241B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114702506B (en) * 2022-03-01 2023-08-22 郑州大学 11-carbonyl-20-ethoxy source oridonin and 14-OH esterified serial derivatives and application thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108299458B (en) * 2017-12-28 2020-10-02 青岛海洋生物医药研究院股份有限公司 Oridonin derivative and preparation method and application thereof
CN110229168B (en) * 2019-06-25 2021-12-31 郑州大学 11, 20-dicarbonyl economic oridonin and L-amino acid-14-ester trifluoroacetate thereof

Also Published As

Publication number Publication date
CN113004241A (en) 2021-06-22

Similar Documents

Publication Publication Date Title
CN111171080B (en) High-efficiency low-toxicity anticancer compound synthesized by autocatalysis in cells and living bodies and synthesis method thereof
CN102977068A (en) Nitric oxide donor type isochromanone derivatives, preparation methods and uses thereof
CN113004241B (en) 11, 20-dicarbonyl economic oridonin 14-O-benzoic acid esterified derivative and preparation method and application thereof
CN114736214B (en) Sesquiterpene derivative, pharmaceutical composition thereof, and preparation method and application thereof
CN114907417B (en) Tetravalent platinum ternary complex containing artesunate and nonsteroidal anti-inflammatory drug as well as preparation method and application thereof
CN110028546B (en) Cyclopentane-polyhydrophenanthrene framework compound with function of regulating blood coagulation factor VIII level to play anti-tumor role and application thereof
CN106588945A (en) Aspirin-anticancer drug conjugate, and synthetic method and application thereof
JP2006518767A (en) Flavone acetic acid analogues and methods of use
CN111253411B (en) Berberine linoleic acid conjugate and preparation method and application thereof
CN110256402B (en) Lipoic acid hydroxylamine derivatives and preparation method and application thereof
CN106317033B (en) Silybin 23-substituted derivative and preparation method and application of injection thereof
CN113173964A (en) Anti-tumor betulin derivative and preparation method thereof
CN111777577A (en) Taxol derivative and application thereof in preparation of medicine for preventing and treating human malignant tumor
CN103145636A (en) 1,4-diacyl-3,6-diphenyl-1,4-dihydrotetrazine compound as well as preparation method and application thereof
CN112979672B (en) 11, 20-dicarbonyl oridonin 14-O esterified series derivatives and application thereof
CN109206469B (en) Glycyrrhetinic acid derivative and preparation method and application thereof
CN106588826B (en) Aspirin taxol anticancer drug conjugate, synthetic method and its application
CN110078770B (en) Compound with quinolinone tetravalent platinum structure, preparation method and application thereof in preparation of antitumor drugs
CN111574377B (en) O-14 benzoic acid esterified derivative of isodon leptostachya, preparation method and application thereof
EP1634878A1 (en) Coumarins compounds, the preparation and the use thereof
CN106928224B (en) Indoles Sophoridine derivative and preparation method thereof
CN114478566B (en) Derivative for eliminating hydroxyl at 1-position of oridonin and application thereof
CN115073355B (en) Cycloheptene-aza-oxaditerpenoid derivative, pharmaceutical composition thereof and application thereof in pharmacy
CN108727245B (en) Salicylic acid compound and preparation method and application thereof
CN112500288B (en) Preparation method of trans-1,3-dilinolein

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant